Alamar Biosciences (NASDAQ:ALMR – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14, Zacks reports.
Alamar Biosciences Price Performance
NASDAQ ALMR traded down $0.47 during trading hours on Monday, reaching $27.99. The company’s stock had a trading volume of 270,182 shares, compared to its average volume of 298,409. The stock has a market capitalization of $1.94 billion and a price-to-earnings ratio of -16.09. Alamar Biosciences has a 1-year low of $18.84 and a 1-year high of $29.43. The firm has a 50-day moving average price of $24.43.
Wall Street Analyst Weigh In
ALMR has been the topic of a number of research reports. Zacks Research raised Alamar Biosciences to a “hold” rating in a report on Wednesday, May 13th. JPMorgan Chase & Co. started coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 target price on the stock. Bank of America assumed coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus initiated coverage on shares of Alamar Biosciences in a research note on Tuesday, May 12th. They set a “buy” rating and a $28.00 price objective for the company. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.
About Alamar Biosciences
Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.
See Also
- Five stocks we like better than Alamar Biosciences
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Alamar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alamar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
